The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

This week we welcomed the federal government's announcement that a respiratory syncytial virus (RSV) vaccine for pregnant women would be included on ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

It has heavily invested in research and development and made strategic acquisitions, enhancing its portfolio with key products such as the RSV vaccine Abrysvo, the migraine treatment Nurtec ODT ...

ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included thos NEW YORK, October 15, 2024--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer ("Tim ...

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million.

Pfizer's RSV vaccine Abrysvo – given to the mother during pregnancy – is also an option for protecting newborns and infants from RSV disease in the first six months of life. Nearly all ...